Jean-Chrétien Norreel

Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France.

PRIMAVERIS SAS (PRIMAVERIS) is the venture capital subsidiary of Proxipaca Finance SA in France. The firm was created in 2001 under the leadership of the Provence Alpes Cote d'Azur region, the Caisse d'Epargne Provence Alpes Corse and the Caisse des Dépôts et Consignations. Based in Marseille, PRIMAVERIS specializes in financing the creation of technology companies in the Provence/Alpes/Cote d'Azur region. The firm has partnerships with three incubators in the region, IMPULSE, l'Incubateur PACA-EST and INCUBATEUR Multimédia Belle-de-Mai.

Beckman Coulter, Inc. manufactures and distributes biomedical testing instrument systems and general biomedical research products. It develops and markets products that simplify, automate and innovate complex biomedical testing. The firm’s systems operate in both diagnostics and life sciences laboratories on seven continents. Its products improve the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery. The company was founded in 1935 by Arnold O. Beckman and is headquartered in Brea, CA.

Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products.

PROENCIA SA (PROENCIA) is the Marseille-based venture capital subsidiary of Proxipaca Finance SA in France. The firm was created in 2001 when the Provence/Alpes/Cote d'Azur region, the Caisse d'Epargne Provence/Alpes/Corse and the Caisse des Dépôts et Consignations agreed to establish PROENCIA to assist very small businesses in creation, development or recovery stage.

Proxipaca Finance SA is a holding French company. The private company is based in Marseille, France. and has subsidiaries in France. The CEO of the company is Cyril Rocher.

HalioDxinvest SAS develops and researches biotechnology products. The company was incorporated on October 17, 2014 and is headquartered in Marseille, France.

Part of QIAGEN NV, Ipsogen, Inc. is a company that develops and markets molecular diagnostic tests for leukemia and breast cancer. The company is based in Stamford, CT. The company was founded by Vincent Fert.

Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom.

Esperante BV (Esperante) is a Dutch based venture capital firm which was founded by Dean Slagel in 2004. Esperante is a seed investor which invests in emerging biotechnology companies engaged in the development of novel therapeutics in areas of major unmet medical need. The firm has a portfolio of investments across France, the UK and the US. The firm provides investee companies with extended management resources, particularly in business development, as a complement to their financial contribution. They also conduct scientific and intellectual property evaluations using confidential life science industry consultants.

Altacor Ltd. operates as a specialist ophthalmology company develops and markets a portfolio of products in the fields of dry eye, glaucoma and ocular infection. The company was founded by Francesca Elizabeth Crawford and David Francis Alcraft in 2007 and is headquartered in Theale, the United Kingdom.

Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom.

Esperante Ltd. operates as a venture investment company controlled by C&P Group Holdings. The company was founded on April 29, 1986 and is headquartered in Maidenhead, the United Kingdom.

Tillotts Pharma AG manufactures pharmaceuticals for treatment of gastrointestinal diseases. The firm specializes in the therapy of the lower gastrointestinal tract. It offers Asacol, Entocort, Colpermin, Tillhepo and VistaPrep. The company was founded in 1986 and is headquartered in Ziefen, Switzerland.

Ferring Pharmaceuticals Ltd. manufactures and produces pharmaceutical products. It offers Zomacton (somatropin) for that treatment of growth failure in children and for girl’s diagnosed with Turners syndrome; GONAPEPTYL (triptorelin), a GnRH agonist that is used for the treatment of children with central precocious puberty; Testim (testosterone gel), a hydroalcoholic topical gel; and PENTASA (mesalazine), which is used for the treatment of inflammatory bowel diseases. The company was founded in 1975 and is headquartered in Middlesex, the United Kingdom.

Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom.

Haemostatix Ltd. designs and develops solutions for haemostasis and thrombosis. Its products include Rapid and effective haemostatic action which is new class of topical coagulant or haemostat that is applied directly to a wound during surgery to control bleeding, and ready-to-use formulations, blood-free ingredients and a new class with a unique mode of action. The company was founded by Sarah Middleton and Alison Goodall in 2003 and is headquartered in Nottingham, the United Kingdom.